

Table S2. Medical and surgical conditions and growth measurements during follow up

Complication	Condition	Lactoferrin	Placebo	P
		n/N (%)	n/N (%)	
Metabolic	Jaundice	63/93 (67.7%)	66/95 (69.5%)	0.875
	Anemia	28/93 (30.1%)	19/95 (20.0%)	0.333
	Hypoglycemia	19/93 (20.4%)	22/95 (23.2%)	0.725
	Electrolyte disturbance	13/93 (14.0%)	17/95 (17.9%)	0.552
Pulmonary	Hyaline membrane disease or respiratory distress syndrome	22/93 (23.4%)	24/95 (25.3%)	0.866
	Pneumonia	6/93 (6.5%)	1/95 (1.1%)	0.063
	Bronchopulmonary dysplasia	4/93 (4.3%)	7/95 (7.4%)	0.537
	Pneumothorax	0/93 (0.0%)	4/95 (4.2%)	0.121
Cardiac	Symptomatic patent ductus arteriosus	4/93 (4.3%)	9/95 (9.5%)	0.250
	Congenital heart defect	6/93 (6.5%)	5/95 (5.3%)	0.766
Neurological	Intraventricular hemorrhage	10/93 (10.8%)	12/95 (12.6%)	0.821
	Hypoxic-ischemic encephalopathy	1/93 (1.1%)	1/95 (1.1%)	1.000

Other	Periventricular leukomalacia	0/93 (0.0%)	3/95 (3.2%)	0.246
	Meningitis	0/93 (0.0%)	1/95 (1.1%)	1.000
	Surgical procedures	5/93 (5.4%)	4/95 (4.2%)	0.746
	NEC	3/93 (3.2%)	2/95 (2.1%)	0.681
	ROP	8/93 (8.6%)	5/95 (5.3%)	0.403
Weight (g) at 1mo, mean $\pm$ SD (n)*	501-1000 g	1053 $\pm$ 109 (4)	985 $\pm$ 62 (6)	0.577
	1001-1500 g	1727 $\pm$ 89 (22)	1695 $\pm$ 56 (28)	0.754
	1501-2000 g	2342 $\pm$ 50 (32)	2224 $\pm$ 88 (28)	0.235
	2001-2500 g	2714 $\pm$ 145 (11)	2841 $\pm$ 93 (15)	0.446
Weight (g) at 3mo, mean $\pm$ SD (n)*	501-1000 g	2670 $\pm$ 267 (4)	2654 $\pm$ 285 (5)	0.969
	1001-1500 g	3666 $\pm$ 138 (21)	4010 $\pm$ 111 (24)	0.055
	1501-2000 g	4588 $\pm$ 108 (31)	4551 $\pm$ 100 (33)	0.802
	2001-2500 g	5033 $\pm$ 339 (8)	5509 $\pm$ 190 (12)	0.203

NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; * number of infants evaluated at 1 and 2 months of follow up